Lauren S. Akesson
Research Subjects
Research Interests
Lauren S. Akesson has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Crystle Lee
Victorian Clinical Genetics Services, Murdoch Children's Research Institute Royal Children's Hospital Melbourne Victoria Australia
2 shared publicationsDavid Francis
Victorian Clinical Genetics Services Murdoch Children's Research Institute Parkville Victoria Australia
2 shared publicationsSebastian Lunke
Victorian Clinical Genetics Services, Murdoch Children's Research Institute Royal Children's Hospital Melbourne Victoria Australia
2 shared publications- Adam Bournazos
The University of Sydney, Faculty of Medicine and Health, School of Medical Sciences, Sydney, Australia
1 shared publication Alice Dudgeon
Tasmanian Clinical Genetics Service Consumer Reference Group, Menzies Institute for Medical Research, University of Tasmania
1 shared publicationAlisha Monaco
Victorian Clinical Genetics Services, Murdoch Children's Research Institute Royal Children's Hospital Melbourne Victoria Australia
1 shared publication
Latest Publications
- Open Access
Developing best practice rare disease diagnostic care models in a real-world rural/regional setting
Background Although individually rare, collectively rare diseases are more common than diabetes mellitus. The diagnostic odyssey for rare diseases is typically prolonged. Aim We aimed to hear the voice of rare disease stakeholders to provide evidence for strategies to improve rare disease care in Tasmania, Australia. Methods Mixed methods research with surveys, focus groups, and interviews captured the voice of healthcare consumers with rare disease, their families, and their caregivers, as well as consumer advocates, community reference group, rare disease researchers, and healthcare professionals. Results We undertook 1,014 stakeholder consultations. Participants described elements of the diagnostic pathway that worked well, as well as barriers to diagnosis. Those affected by rare disease and their caregivers emphasised the need for healthcare providers to listen and respond to consumer concerns. Collectively, stakeholders reported that challenges in rare disease diagnosis in Tasmania include difficulties accessing timely primary and specialist health care, low awareness of rare disease among health professionals in Tasmania (including how to identify people with possible rare disease and what to do next), difficulty in accessing diagnostic testing, cost and geographic barriers in accessing diagnostic care, a lack of epidemiologic information on rare disease in Tasmania and the breakdown in care and support from the health system when transitioning from paediatric to adult services. Discussion Many participant concerns that fall under the system responsibility of the Tasmanian Government could be addressed by establishing a Tasmanian Rare Care Centre. The centre could adopt principles from cancer care, such as patient-centred care, safe and quality care, multidisciplinary care, supportive care, care coordination, communication, and research and clinical trials. Other concerns, such as the equitable implementation of emerging diagnostic technologies and the education and training of non-genetics practitioners, will require national leadership and interjurisdictional cooperation to address. The Known Rare diseases are a global health priority. The diagnostic odyssey is often prolonged, affecting rare disease care. The New Stakeholder consultation revealed that individuals affected by rare diseases and their families and caregivers often feel that they are not listened to, that their care is fragmented, and that non-genetics healthcare providers have limited awareness and understanding of rare disease. The Implications Many concerns raised by rare disease stakeholders could be addressed by establishing a Tasmanian Rare Care Centre.
Open AccessDeveloping best practice rare disease diagnostic care models in a real-world rural/regional setting
Background Although individually rare, collectively rare diseases are more common than diabetes mellitus. The diagnostic odyssey for rare diseases is typically prolonged. Aim We aimed to hear the voice of rare disease stakeholders to provide evidence for strategies to improve rare disease care in Tasmania, Australia. Methods Mixed methods research with surveys, focus groups, and interviews captured the voice of healthcare consumers with rare disease, their families, and their caregivers, as well as consumer advocates, community reference group, rare disease researchers, and healthcare professionals. Results We undertook 1,014 stakeholder consultations. Participants described elements of the diagnostic pathway that worked well, as well as barriers to diagnosis. Those affected by rare disease and their caregivers emphasised the need for healthcare providers to listen and respond to consumer concerns. Collectively, stakeholders reported that challenges in rare disease diagnosis in Tasmania include difficulties accessing timely primary and specialist health care, low awareness of rare disease among health professionals in Tasmania (including how to identify people with possible rare disease and what to do next), difficulty in accessing diagnostic testing, cost and geographic barriers in accessing diagnostic care, a lack of epidemiologic information on rare disease in Tasmania and the breakdown in care and support from the health system when transitioning from paediatric to adult services. Discussion Many participant concerns that fall under the system responsibility of the Tasmanian Government could be addressed by establishing a Tasmanian Rare Care Centre. The centre could adopt principles from cancer care, such as patient-centred care, safe and quality care, multidisciplinary care, supportive care, care coordination, communication, and research and clinical trials. Other concerns, such as the equitable implementation of emerging diagnostic technologies and the education and training of non-genetics practitioners, will require national leadership and interjurisdictional cooperation to address. The Known Rare diseases are a global health priority. The diagnostic odyssey is often prolonged, affecting rare disease care. The New Stakeholder consultation revealed that individuals affected by rare diseases and their families and caregivers often feel that they are not listened to, that their care is fragmented, and that non-genetics healthcare providers have limited awareness and understanding of rare disease. The Implications Many concerns raised by rare disease stakeholders could be addressed by establishing a Tasmanian Rare Care Centre.
- Open Access
- 15 March 2022
- Published by Wiley in JIMD Reports
- Vol. 63 (3) , 240-249
Distinct diagnostic trajectories in NBAS‐associated acute liver failure highlights the need for timely functional studies
Variants of uncertain significance (VUS) are commonly found following genomic sequencing, particularly in ethnically diverse populations that are underrepresented in large population databases. Functional characterization of VUS may assist in variant reclassification, however these studies are not readily available and often rely on research funding and good will. We present four individuals from three families at different stages of their diagnostic trajectory with recurrent acute liver failure (RALF) and biallelic NBAS variants, confirmed by either trio analysis or cDNA studies. Functional characterization was undertaken, measuring NBAS and p31 levels by Western blotting, demonstrating reduced NBAS levels in two of three families, and reduced p31 levels in all three families. These results provided functional characterization of the molecular impact of a missense VUS, allowing reclassification of the variant and molecular confirmation of NBAS‐associated RALF. Importantly, p31 was decreased in all individuals, including an individual with two missense variants where NBAS protein levels were preserved. These results highlight the importance of access to timely functional studies after identification of putative variants, and the importance of considering a range of assays to validate variants whose pathogenicity is uncertain. We suggest that funding models for genomic sequencing should consider incorporating capabilities for adjunct RNA, protein, biochemical, and other specialized tests to increase the diagnostic yield which will lead to improved medical care, increased equity, and access to molecular diagnoses for all patients.
- 15 March 2022
- Published by Wiley in JIMD Reports
- Vol. 63 (3) , 240-249
Open AccessDistinct diagnostic trajectories in NBAS‐associated acute liver failure highlights the need for timely functional studies
Variants of uncertain significance (VUS) are commonly found following genomic sequencing, particularly in ethnically diverse populations that are underrepresented in large population databases. Functional characterization of VUS may assist in variant reclassification, however these studies are not readily available and often rely on research funding and good will. We present four individuals from three families at different stages of their diagnostic trajectory with recurrent acute liver failure (RALF) and biallelic NBAS variants, confirmed by either trio analysis or cDNA studies. Functional characterization was undertaken, measuring NBAS and p31 levels by Western blotting, demonstrating reduced NBAS levels in two of three families, and reduced p31 levels in all three families. These results provided functional characterization of the molecular impact of a missense VUS, allowing reclassification of the variant and molecular confirmation of NBAS‐associated RALF. Importantly, p31 was decreased in all individuals, including an individual with two missense variants where NBAS protein levels were preserved. These results highlight the importance of access to timely functional studies after identification of putative variants, and the importance of considering a range of assays to validate variants whose pathogenicity is uncertain. We suggest that funding models for genomic sequencing should consider incorporating capabilities for adjunct RNA, protein, biochemical, and other specialized tests to increase the diagnostic yield which will lead to improved medical care, increased equity, and access to molecular diagnoses for all patients.
- 9 September 2020
- Published by Hindawi Limited in Human Mutation
- Vol. 41 (11) , 1884-1891
Rapid exome sequencing and adjunct RNA studies confirm the pathogenicity of a novel homozygous ASNS splicing variant in a critically ill neonate
Rapid genomic diagnosis programs are transforming rare disease diagnosis in acute pediatrics. A ventilated newborn with cerebellar hypoplasia underwent rapid exome sequencing (75 h), identifying a novel homozygous ASNS splice‐site variant (NM_133436.3:c.1476+1G>A) of uncertain significance. Rapid ASNS splicing studies using blood‐derived messenger RNA from the family trio confirmed a consistent pattern of abnormal splicing induced by the variant (cryptic 5′ splice‐site or exon 12 skipping) with absence of normal ASNS splicing in the proband. Splicing studies reported within 10 days led to reclassification of c.1476+1G>A as pathogenic at age 27 days. Intensive care was redirected toward palliation. Cost analyses for the neonate and his undiagnosed, similarly affected deceased sibling, demonstrate that early diagnosis reduced hospitalization costs by AU$100,828. We highlight the diagnostic benefits of adjunct RNA testing to confirm the pathogenicity of splicing variants identified via rapid genomic testing pipelines for precision and preventative medicine.
- 9 September 2020
- Published by Hindawi Limited in Human Mutation
- Vol. 41 (11) , 1884-1891
Rapid exome sequencing and adjunct RNA studies confirm the pathogenicity of a novel homozygous ASNS splicing variant in a critically ill neonate
Rapid genomic diagnosis programs are transforming rare disease diagnosis in acute pediatrics. A ventilated newborn with cerebellar hypoplasia underwent rapid exome sequencing (75 h), identifying a novel homozygous ASNS splice‐site variant (NM_133436.3:c.1476+1G>A) of uncertain significance. Rapid ASNS splicing studies using blood‐derived messenger RNA from the family trio confirmed a consistent pattern of abnormal splicing induced by the variant (cryptic 5′ splice‐site or exon 12 skipping) with absence of normal ASNS splicing in the proband. Splicing studies reported within 10 days led to reclassification of c.1476+1G>A as pathogenic at age 27 days. Intensive care was redirected toward palliation. Cost analyses for the neonate and his undiagnosed, similarly affected deceased sibling, demonstrate that early diagnosis reduced hospitalization costs by AU$100,828. We highlight the diagnostic benefits of adjunct RNA testing to confirm the pathogenicity of splicing variants identified via rapid genomic testing pipelines for precision and preventative medicine.
- 31 August 2020
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 57 (7) , 1109-1112
Microarray diagnosis of autoimmune polyendocrinopathy‐candidiasis‐ectodermal dystrophy caused by a novel homozygous intragenic AIRE deletion
- 31 August 2020
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 57 (7) , 1109-1112
Microarray diagnosis of autoimmune polyendocrinopathy‐candidiasis‐ectodermal dystrophy caused by a novel homozygous intragenic AIRE deletion